3D Animation of Polycomb Protein EED bound by Tazemetostat

This is a 3D animation depicting Polycomb Protein EED bound by Tazemetostat. Tazemetostat is a first in class inhibitor of EED, a promising oncology medication developed by Epizyme.

Protein Description

Polycomb protein EED is a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein interacts with enhancer of zeste 2, the cytoplasmic tail of integrin β7, immunodeficiency virus type 1 (HIV-1) MA protein, and histone deacetylase proteins. This protein mediates repression of gene activity through histone deacetylation, and may act as a specific regulator of integrin function. Two transcript variants encoding distinct isoforms have been identified for this gene.

Mechanism of Action

Overexpression and somatic heterozygous mutations of EZH2, the catalytic subunit of polycomb repressive complex 2 (PRC2), are associated with several tumor types. EZH2 inhibitor, EPZ-6438 (tazemetostat), demonstrated clinical efficacy in patients with acceptable safety profile as monotherapy. EED, another subunit of PRC2 complex, is essential for its histone methyltransferase activity through direct binding to trimethylated lysine 27 on histone 3 (H3K27Me3). Tazemetostat  is a first-in-class potent, selective, and orally bioavailable EED inhibitor used in the treatment of B Cell Lymphoma.

, , , , ,

No comments yet.

Leave a Reply

Powered by WordPress. Designed by WooThemes